Eikon Therapeutics is using super-resolution microscopy for drug development. Advances in super-resolution fluorescence microscopy has now made it possible to follow the dynamics of individual proteins in living cells. Measurements from single particle tracking enable the calculation of protein angular movements, on-rates/off-rates and residence times for binding events. Eikon is using this technology to assess protein dynamics and reveal novel biological mechanisms of action, thus providing new therapeutic approaches. This requires the combination of engineering, computation, biology, medicinal chemistry and pharmacology expertise. Eikon’s pipeline is designed to achieve effective therapeutics for unmet medical needs.

<p>Eikon Therapeutics is using super-resolution microscopy for drug development. Advances in super-resolution fluorescence microscopy has now made it possible to follow the dynamics of individual proteins in living cells. Measurements from single particle tracking enable the calculation of protein angular movements, on-rates/off-rates and residence times for binding events. Eikon is using this technology to assess protein dynamics and reveal novel biological mechanisms of action, thus providing new therapeutic approaches. This requires the combination of engineering, computation, biology, medicinal chemistry and pharmacology expertise. Eikon’s pipeline is designed to achieve effective therapeutics for unmet medical needs.</p>


Eikon Therapeutics

Founded: 2019
Location: Hayward, CA
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Undisclosed
Drug types: ONC
Lead product: Undisclosed
Funding: $106M C Jun 2023; $518M B Jan 2022; $148M A May 2021

Drug notes:

About:

Jobs: